DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Increased by Brooktree Capital Management

Brooktree Capital Management boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 33.9% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,636 shares of the medical device company’s stock after purchasing an additional 3,453 shares during the period. DexCom comprises approximately 0.8% of Brooktree Capital Management’s holdings, making the stock its 20th largest position. Brooktree Capital Management’s holdings in DexCom were worth $1,060,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in DXCM. Signaturefd LLC grew its holdings in shares of DexCom by 30.3% during the 4th quarter. Signaturefd LLC now owns 6,561 shares of the medical device company’s stock valued at $510,000 after acquiring an additional 1,526 shares in the last quarter. Cibc World Markets Corp boosted its position in DexCom by 12.4% during the fourth quarter. Cibc World Markets Corp now owns 70,763 shares of the medical device company’s stock valued at $5,503,000 after purchasing an additional 7,786 shares during the last quarter. SlateStone Wealth LLC purchased a new position in DexCom in the fourth quarter valued at about $205,000. Patten & Patten Inc. TN increased its position in DexCom by 5.0% in the 4th quarter. Patten & Patten Inc. TN now owns 74,811 shares of the medical device company’s stock worth $5,818,000 after purchasing an additional 3,570 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. raised its stake in shares of DexCom by 30.5% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 16,159 shares of the medical device company’s stock worth $1,257,000 after purchasing an additional 3,778 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This represents a 9.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 104,657 shares of company stock worth $8,019,422 over the last 90 days. Insiders own 0.30% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $71.35 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a 50 day simple moving average of $83.82 and a 200 day simple moving average of $76.94. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a market cap of $27.88 billion, a P/E ratio of 49.90, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Sell-side analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on DXCM. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and raised their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.